Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis

NCT00289978 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00289978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00289978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2006
Completion date
July 31, 2009
Enrollment
1,272 (actual)
Sites
115

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis